In a filing, Century Therapeutics Inc revealed its President and CEO Pfeiffenberger Brent unloaded Company’s shares for reported $16135.0 on May 16 ’25. In the deal valued at $0.55 per share,29,552 shares were sold. As a result of this transaction, Pfeiffenberger Brent now holds 1,682,258 shares worth roughly $1.01 million.
Then, Pfeiffenberger Brent bought 29,552 shares, generating $16,138 in total proceeds.
Before that, Farid Adrienne sold 1,024 shares. Century Therapeutics Inc shares valued at $563 were divested by the Chief Operations Officer at a price of $0.55 per share. As a result of the transaction, Farid Adrienne now holds 250,693 shares, worth roughly $0.15 million.
Rodman & Renshaw initiated its Century Therapeutics Inc [IPSC] rating to a Buy in a research note published on August 08, 2024; the price target was $6. A number of analysts have revised their coverage, including JP Morgan’s analysts, who decreased its forecast for the stock in late August from “an Overweight” to “a Neutral”. Chardan Capital Markets began covering IPSC with “Buy” recommendation on December 27, 2022. Guggenheim started covering the stock on October 31, 2022. It rated IPSC as “a Buy”.
Price Performance Review of IPSC
On Tuesday, Century Therapeutics Inc [NASDAQ:IPSC] saw its stock jump 8.24% to $0.60. Over the last five days, the stock has gained 14.07%. Century Therapeutics Inc shares have fallen nearly -40.59% since the year began. Nevertheless, the stocks have fallen -80.83% over the past one year. While a 52-week high of $3.47 was reached on 01/08/25, a 52-week low of $0.34 was recorded on 04/09/25. SMA at 50 days reached $0.5241, while 200 days put it at $1.0915.
Levels Of Support And Resistance For IPSC Stock
The 24-hour chart illustrates a support level at 0.5650, which if violated will result in even more drops to 0.5300. On the upside, there is a resistance level at 0.6350. A further resistance level may holdings at 0.6700. The Relative Strength Index (RSI) on the 14-day chart is 62.56, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0324, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 21.87%. Stochastics %K at 82.52% indicates the stock is a selling.
The most recent change occurred on October 10, 2022 when Canaccord Genuity began covering the stock and recommended ‘”a Buy”‘ rating along with a $28 price target.
